Unidad Inmunología e Histocompatibilidad, Hospital Dr. Carlos G. Durand, Buenos Aires, Argentina. E-mail:
Immunology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Medicina (B Aires). 2021;81(6):1065-1068.
Germline gain-of-function (GOF) mutation of the signal transducer and activator of transcription 3 (STAT3) gene causes a disease clinically characterized by a significant lymphoproliferation, including lymphadenopathy and/or hepatosplenomegaly, as well as childhood onset autoimmunity. Here we present an adult patient who, during his early years of life, presented recurrent infections, autoimmune hemolytic anemia and benign lymphoproliferative disease, characterized by hepatosplenomegaly and lymphadenopathy, being diagnosed with common variable immunodeficiency (CVID) at 13 years of age. He was diagnosed with lymphocytic interstitial pneumonia at the age of 20. When he was 40 years old, after a diagnostic review, it was decided to perform genetic studies. A heterozygous mutation in STAT3 NM_003150 c.2141C>T, p.P714L was detected by whole exome sequencing and validated by Sanger. Previously published functional studies performed in two siblings showed that this mutation resulted in gain-of-function. They were initially diagnosed with autoimmune lymphoproliferative syndrome, and later with STAT3 GOF as a second genetic defect. Our patient developed severe pulmonary disease and died, without access to treatment targeted to his molecular defect due to the advanced nature of his pulmonary involvement and the fact that many of the therapies were still in development at that time. The diagnosis of STAT3 GOF mutations should be suspected in patients with early-onset of lymphoproliferative disease, autoimmunity and hypogammaglobulinemia. This must be considered especially in the group of CVID patients with these characteristics, in order to allow the implementation of treatments targeting the molecular defect (JAK inhibitors and Il-6 receptor antagonists) that could modify the disease evolution.
信号转导子和转录激活子 3(STAT3)基因的胚系获得性功能(GOF)突变导致一种疾病,其临床特征为显著的淋巴组织增生,包括淋巴结病和/或肝脾肿大,以及儿童期自身免疫。在这里,我们介绍了一位成年患者,他在早年曾反复感染、自身免疫性溶血性贫血和良性淋巴组织增生性疾病,表现为肝脾肿大和淋巴结病,13 岁时被诊断为普通变异性免疫缺陷(CVID)。20 岁时,他被诊断为淋巴细胞性间质性肺炎。当他 40 岁时,经过诊断回顾,决定进行基因研究。通过外显子组测序检测到 STAT3 NM_003150 c.2141C>T,p.P714L 的杂合突变,并通过 Sanger 验证。之前在两个兄弟姐妹中进行的功能研究表明,这种突变导致了功能获得。他们最初被诊断为自身免疫性淋巴组织增生综合征,后来又被诊断为 STAT3 GOF 作为第二个遗传缺陷。我们的患者发展为严重的肺部疾病并死亡,由于他的肺部受累已经很严重,而且当时许多治疗方法仍在开发中,因此无法获得针对他的分子缺陷的靶向治疗。在早期出现淋巴组织增生性疾病、自身免疫和低丙种球蛋白血症的患者中,应怀疑存在 STAT3 GOF 突变。在具有这些特征的 CVID 患者中,尤其应考虑这一点,以便能够实施针对分子缺陷的治疗(JAK 抑制剂和 IL-6 受体拮抗剂),从而改变疾病的演变。